Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Francois Cherifi"'
Autor:
Francois Cherifi, Sophie Lefevre Arbogast, Jonaz Font, Justine Lequesne, Stephanie Becourt, Cyril Abdeddaim, Yori Gidron, Florence Joly
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0a921da4c883b77a64d6dbfccd43aaa
https://doi.org/10.1136/ijgc-2022-esgo.550
https://doi.org/10.1136/ijgc-2022-esgo.550
Autor:
Lucia Carril, Emeline Colomba, Carmen Romero-Ferreiro, Luigi Cerbone, Raffaele Ratta, Philippe Barthélémy, Clarisse Vindry, Francois Cherifi, Elouen Boughalem, Claude Linassier, Giuseppe Fornarini, Marine Gross-Goupil, Carolina Saldana, Maria Cruz Martin Soberón, Guillermo de Velasco, Cristina Pernaut, Carolina Alves Costa Silva, Ronan Flippot, Bernard Escudier, Laurence Albiges
Publikováno v:
Journal of Clinical Oncology. 40:320-320
320 Background: Immune checkpoint combination therapy (ICI-combo) is the new standard of care for mRCC in first-line setting. However, pts with poor PS (≥2) were excluded from pivotal trials. Hence, the activity and safety of ICI-combo in this grou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf0e19698b730a6fee5aec68bdf00cd
https://doi.org/10.1200/jco.2022.40.6_suppl.320
https://doi.org/10.1200/jco.2022.40.6_suppl.320
Autor:
Florian Quilan, Justine Lequesne, François Cherifi, Etienne Bastien, Adeline Morel, Corinne Delcambre, Angélique Da Silva, Jean‐Michel Grellard, Alexandra Leconte, Audrey Faveyrial, Bénédicte Clarisse, Florence Joly
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17603-17612 (2023)
Abstract Introduction COVID‐19 outbreak rapidly spread since early 2020 leading to the implementation of nationwide lockdowns. To cope with this sudden change, management guidelines were quickly published to adapt oncological care, with potential i
Externí odkaz:
https://doaj.org/article/ba36f22363ca4ebf8536f1892062ffee
Autor:
Jordane Divoux, Romane Florent, Margaux Jacobs, Justine Lequesne, Jean-Michel Grellard, Chankannira San, Sara Grossi, Katia Kerdja, Bénédicte Clarisse, Gwenaelle Boudier, François Cherifi, Mélanie Briand, Enora Dolivet, Alisson Johnson, Brice Dubois, Valentin Harter, Joëlle Lacroix, Charlotte Raboutet, Brigitte Marie, Nathalie Rousseau, Cécile Blanc-Fournier, Dominique Vaur, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald, George Emile
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Triple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and high risk of metastasis. The current neoadjuvant
Externí odkaz:
https://doaj.org/article/ca31ade11a73463e975df48ff00e460c
Autor:
François Cherifi, Angélique Da Silva, Alison Johnson, Cécile Blanc-Fournier, Olivia Abramovici, Antonin Broyelle, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Clémence Boscher, Coraline Dubot-Poitelon, Pauline Rottier, Justine Lequesne, George Emile
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted
Externí odkaz:
https://doaj.org/article/729e7bcb52cf4560a57a3e58bf74b4ff
Autor:
Pauline Rottier, George Emile, Alison Johnson, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Coraline Dubot-Poitelon, Louis Boismoreau, François Cherifi, Justine Lequesne, Angélique Da Silva
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundCyclin dependent kinase inhibitors (CdK4/6i) changed the course of hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC). To date, no factors have been shown to predict response to CdK4/6i. Neutrophil-to-lymph
Externí odkaz:
https://doaj.org/article/d562fdba4d99430585cc0e12cca5da20
Autor:
François Cherifi, Sophie Lefevre Arbogast, Jonaz Font, Cyril Abdeddaim, Stephanie Becourt, Nicolas Penel, Elodie Coquan, Justine Lequesne, Yori Gidron, Florence Joly
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveIdentifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low va
Externí odkaz:
https://doaj.org/article/4fa3cc2ceb7f47df9f271880fc3dd061